A pioneering injectable hydrogel shows great promise in preclinical studies for the treatment of osteoporosis. This innovative treatment not only relieves joint pain, but also effectively repairs damaged cartilage, providing a dual-action approach to a condition that affects millions worldwide.
Understanding osteoporosis
Osteoporosisoften oversimplified as “wear and tear,” is a complex degenerative joint disease. It involves a defect in the cells that maintain cartilage (chondrocytes), causing the cartilage to break down so that bones begin to rub against each other. Current treatments focus primarily on pain management and do not stop disease progression, often necessitating joint replacement surgery.
A new approach to dual action
- Targeting pain and damage: Researchers have identified a specific protein, Nav1.7, that is overactive in osteoarthritis. This increased activity not only signals pain, but also prompts chondrocytes to destroy cartilage. Blocking Nav1.7 provides a unique dual-purpose target.
- Reuse of medication: Lacosamide, an existing drug for treating epilepsy, has been shown to be highly effective at low concentrations in blocking Nav1.7. It stimulates the release of protective proteins such as HSP70 and midkine, which help in tissue repair and reduce inflammation.
- Advanced Hydrogel Delivery: To ensure effective drug delivery and local retention, a specialized hydrogel made of collagen II was developed. This heat-responsive gel hardens when injected into the joint, creating a reservoir that slowly releases lacosamide over several weeks, turning a daily pill into a long-term topical treatment.
Preclinical results are promising
In preclinical studies, a single injection of lacosamide-loaded hydrogel every four weeks has proven to be more effective in preventing cartilage loss than daily oral medications. The ability of the hydrogel to maintain drug concentration at the site of injury reduces systemic side effects. Because lacosamide has already received FDA approval, the path to clinical trials for osteoporosis patients may be accelerated.
Future outlook
This research represents an important step forward in the treatment of osteoporosis, moving from symptom management to disease modification. By combining advanced biomaterials with current pharmacology, this injectable hydrogel system offers a potential future with fewer medical procedures, fewer side effects, and sustainable structural protection of the joints.
